An open-label study of the human anti-TNF monoclon...[Am J Gastroenterol. 2004] - PubMed Result

NCBI / PubMed A service of the U.S. National Library of Medicine and the National Institutes of Health / My NCBI / [Sign In] [Register] ... After week 4, the dose could be escalated to 40 mg weekly in patients who did not achieve clinical remission,...
http://www.ncbi.nlm.nih.gov/pubmed/15447761/

 

An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's diseas

Home / Pharmaceutical Reports / Pharmaceutical report sourcer / DailyUpdates: Advances for Drug Development / Key Scientific Journal Articles ... After week 4, the dose could be escalated to 40 mg weekly in patients who did not achieve clinical...
http://www.leaddiscovery.co.uk/articles/15447761/

 

Dictionary Contents: C

On-Line Medical Dictionary / C ...
http://cancerweb.ncl.ac.uk/omd/contents/C.html

 

Promising Pivotal Phase III Data Show Abbott's HUMIRA® (adalimumab) Maintained Clinical Remission in Patients with Crohn's Disease Through One Year: May 22, 206

Select a Country | / Site Map | / Contact Us / Print This Page | / Back to Web Page / Home / About Abbott / Products / Science / Global Citizenship / Careers / News & Media / Press Releases / Features / Fact Sheets ... Complete...
http://www.abbott.com/global/url/pressRelease/en_US/60.5:5/Press_Release_0320.htm

 

eMedicine - Crohn Disease : Article by Yung-Hsin CheneMedicine - Crohn Disease : Article by

Home / Specialties / Reference Centers ... Agents such as infliximab, Etanercept and CDP571 are becoming available and showing promising results, with an increased remission rate in 48% at 4 weeks and with complete fistula...
http://www.emedicine.com/radio/topic197.htm